Literature DB >> 3108247

Lethal perinatal osteogenesis imperfecta due to the substitution of arginine for glycine at residue 391 of the alpha 1(I) chain of type I collagen.

J F Bateman, D Chan, I D Walker, J G Rogers, W G Cole.   

Abstract

A baby with the lethal perinatal form of osteogenesis imperfecta was shown to have a structural defect in the alpha 1(I) chain of type I procollagen. Normal and mutant alpha 1(I) CB8 cyanogen bromide peptides, from the helical part of the alpha 1(I) chains, were purified from bone. Amino acid sequencing of tryptic peptides derived from the mutant alpha 1(I) CB8 peptide showed that the glycine residue at position 391 of the alpha 1(I) chain had been replaced by an arginine residue. This substitution accounted for the more basic charged form of this peptide that was observed on two-dimensional electrophoresis of the collagen peptides obtained from the tissues. The substitution was associated with increased enzymatic hydroxylation of lysine residues in the alpha 1(I) CB8 and the adjoining CB3 peptides but not in the carboxyl-terminal CB6 and CB7 peptides. This finding suggested that the sequence abnormality had interfered with the propagation of the triple helix across the mutant region. The abnormal collagen was not incorporated into the more insoluble fraction of bone collagen. The baby appeared to be heterozygous for the sequence abnormality and as the parents did not show any evidence of the defect it is likely that the baby had a new mutation of one allele of the pro-alpha 1(I) gene. The amino acid substitution could result from a single nucleotide mutation in the codon GGC (glycine) to produce the codon CGC (arginine).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3108247

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  The clinical features of osteogenesis imperfecta resulting from a non-functional carboxy terminal pro alpha 1(I) propeptide of type I procollagen and a severe deficiency of normal type I collagen in tissues.

Authors:  W G Cole; P E Campbell; J G Rogers; J F Bateman
Journal:  J Med Genet       Date:  1990-09       Impact factor: 6.318

2.  Osteogenesis imperfecta due to recurrent point mutations at CpG dinucleotides in the COL1A1 gene of type I collagen.

Authors:  C J Pruchno; D H Cohn; G A Wallis; M C Willing; B J Starman; X M Zhang; P H Byers
Journal:  Hum Genet       Date:  1991-05       Impact factor: 4.132

3.  Detection of point mutations in type I collagen by RNase digestion of RNA/RNA hybrids.

Authors:  D K Grange; G S Gottesman; M B Lewis; J C Marini
Journal:  Nucleic Acids Res       Date:  1990-07-25       Impact factor: 16.971

Review 4.  Osteogenesis imperfecta: translation of mutation to phenotype.

Authors:  P H Byers; G A Wallis; M C Willing
Journal:  J Med Genet       Date:  1991-07       Impact factor: 6.318

5.  Perinatal lethal osteogenesis imperfecta (OI type II): a biochemically heterogeneous disorder usually due to new mutations in the genes for type I collagen.

Authors:  P H Byers; P Tsipouras; J F Bonadio; B J Starman; R C Schwartz
Journal:  Am J Hum Genet       Date:  1988-02       Impact factor: 11.025

6.  Variable expression of osteogenesis imperfecta in a nuclear family is explained by somatic mosaicism for a lethal point mutation in the alpha 1(I) gene (COL1A1) of type I collagen in a parent.

Authors:  G A Wallis; B J Starman; A B Zinn; P H Byers
Journal:  Am J Hum Genet       Date:  1990-06       Impact factor: 11.025

7.  Tandem duplication within a type II collagen gene (COL2A1) exon in an individual with spondyloepiphyseal dysplasia.

Authors:  G E Tiller; D L Rimoin; L W Murray; D H Cohn
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

8.  The clinical features of three babies with osteogenesis imperfecta resulting from the substitution of glycine by arginine in the pro alpha 1(I) chain of type I procollagen.

Authors:  W G Cole; C W Chow; J G Rogers; J F Bateman
Journal:  J Med Genet       Date:  1990-04       Impact factor: 6.318

9.  Osteogenesis imperfecta type III: mutations in the type I collagen structural genes, COL1A1 and COL1A2, are not necessarily responsible.

Authors:  G A Wallis; B Sykes; P H Byers; C G Mathew; D Viljoen; P Beighton
Journal:  J Med Genet       Date:  1993-06       Impact factor: 6.318

10.  Frameshift mutation near the 3' end of the COL1A1 gene of type I collagen predicts an elongated Pro alpha 1(I) chain and results in osteogenesis imperfecta type I.

Authors:  M C Willing; D H Cohn; P H Byers
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.